Use of Multiple Sclerosis Drugs Among Pregnant Women

Basic Details
Date Posted
Thursday, December 6, 2018
Status
Complete
Medical Product
alemtuzumab
daclizumab
dalfampridine
dimethyl fumarate
fingolimod
glatiramer acetate
interferon beta-1A
interferon beta-1A/albumin
interferon beta-1B
mitoxantrone
natalizumab
peginterferon beta-1a
teriflunomide
Health Outcome(s)
pregnancy
Description

This report contains estimates of multiple sclerosis (MS) drug use before, during, and after pregnancies resulting in a live-born delivery, among women in the Sentinel Distributed Database (SDD). Data from January 1, 2001 to August 31, 2017 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 20, 2017.

Additional Details
FDA Center
CDER
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Pregnant women and women of reproductive age
Data Sources
Sentinel Distributed Database (SDD)